From: The management strategies of cancer-associated anorexia: a critical appraisal of systematic reviews
Systematic review | Relevant studies, No | Study design (No) | Population | Intervention | Control | Outcome |
---|---|---|---|---|---|---|
Dewey et al., 2007 [17] | 5 | RCT (n = 5) | Incurable or advanced cancer patients with either a reported weight loss of 5% and above or cachexia | Oral fish oil supplementation | Placebo/ active matched control | AE, BC, CR, EE, Fatigue, FS, NS, PS, QoL, SA, Survival, WC |
Baldwin et al., 2012 [19] | 13 | RCT (n = 13) | Adults cancer patients with malnourished or at risk of malnutrition | Dietary advice, oral nutritional supplements, or both | Usual care | NI (ie, weight loss and energy intake), QOL, Survival |
Reid et al., 2012 [20] | 3 | RCT (n = 3) | Advanced or incurable cancer patients with weight loss or cachexia | Thalidomide orally | Placebo/ an alternative experimental treatment modality | AE, BC, Fatigue, FS, GP, PIC, PS, QoL, Survival |
Ruiz et al., 2013 [21] | 35 | RCT (n = 35) | Patients with cancer, AIDS or another underlying pathology related anorexia-cachexia | Megestrol acetate | Placebo/ other active drug treatments/ different doses | AC, AE, MAC, QoL, TSFT, WC |
Chung et al., 2016 [26] | 14 | RCT (n = 14) | Cancer patients with various types, most in moderate to advanced stage | CHM, either in combination with other treatments or used alone | Conventional treatment, placebo, or no treatment. | Fatigue, paresthesias, dysesthesias, chronic pain, anorexia, insomnia, limbs edema, constipation |
Lau et al., 2016 [27] | 13 | RCT (n = 13) | Patients with various types of cancer, near half in moderate to advanced stages | Any form of acupuncture and/or related therapies | Any type of interventions without acupuncture or related treatments | Fatigue, paresthesia, dysesthesias, chronic pain, anorexia, insomnia, limb edema, constipation, QoL |
Bai et al., 2017 [28] | 4 | RCT (N = 3) Randomized crossover Trial (n = 1) | Cancer anorexia-cachexia syndrome (CACS) patients | Anamorelin | Placebo or Anamorelin at various doses | AC, GS, LBM, PS, QoL, Serum biomarkers, WC |
Mochamat et al., 2017 [29] | 21 | RCT (n = 17) Prospective studies (n = 3) Crossover study (n = 1) | Cancer patients with cachexia or cachexia-related symptoms | Vitamin, mineral, proteins, or other dietary supplements | No supplements/ different supplements | AE, AC, LBM, L-carnitine, QoL, Survival, WC, |